Product Description
Mechanisms of Action: MAPK Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Daiichi Sankyo
Company Location: TOKYO M0 103-8426
Company CEO:
Additonal Commercial Interests: None
Clinical Description

Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Non-Small-Cell Lung Cancer|Liver Cancer|Soft Tissue Cancer|Bone Cancer|Sarcoma|Lung Cancer
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2004-001108-11 | P2 |
Terminated |
Lung Cancer|Sarcoma|Soft Tissue Cancer|Liver Cancer|Bone Cancer |
2021-01-13 |
|
CDR0000310138 | P2 |
Completed |
Sarcoma |
2005-12-01 |
|
CDR0000301749 | P2 |
Completed |
Non-Small-Cell Lung Cancer |
2005-05-01 |
|
DAIICHI-1027A-PRT008 | P1 |
Withdrawn |
Oncology Solid Tumor Unspecified |
None |